New York, June 2, 2026, 09:09 EDT
Liquidia Corporation shares were flat in early trading Tuesday after falling hard the day before. Investors are watching for more news from the company on YUTREPIA, its inhaled drug for lung disease. The Nasdaq stock ended Monday at $58.75, off 5.04%, and was last seen at $58.91 in thin premarket action at 6:22 a.m. EDT, according to MarketWatch.
Liquidia has been a top biotech pick for 2026, with the stock gaining about 70% year to date through Monday, Yahoo Finance data show. Shares touched an intraday high of $63.46 last week before pulling back.
Liquidia is set for a business update soon. Chief Executive Roger Jeffs and COO/CFO Michael Kaseta will speak at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, at 12:45 p.m. ET.
Investors want signs the launch curve is still on track. In May, Liquidia posted Q1 YUTREPIA net sales of $129.9 million, net income of $52.9 million and adjusted EBITDA of $71.2 million. Adjusted EBITDA excludes interest, taxes, depreciation, amortization and some other costs. Jeffs said YUTREPIA had “sustained uptake” in pulmonary arterial hypertension and PH-ILD, or pulmonary hypertension linked to interstitial lung disease. GlobeNewswire
Liquidia’s drug is used for high blood pressure in the lungs, which affects the heart. The company said it got over 4,500 unique prescriptions since the June 2025 launch, with around 3,750 patients starting treatment through April 30, 2026.
Analysts are calling the launch a market-share event, not just a matter of earnings. Investor’s Business Daily in May quoted Needham analyst Serge Belanger saying YUTREPIA is expected to claim about 17% of the inhaled-treatment market by the end of 2025, with “broad-based” uptake in both PAH and PH-ILD. Investors
Liquidia is now up against United Therapeutics, which still counts its Tyvaso franchise as the main rival. United posted Tyvaso revenue of $457.5 million for the first quarter, off 2% from last year. The company saw Tyvaso DPI sales rise, making up for some of the 22% fall in nebulized Tyvaso. President and COO Michael Benkowitz called the inhaled prostacyclin market “dynamic” and said Tyvaso DPI has held up. BioSpace
Liquidia director Arthur S. Kirsch filed a Form 144 on Monday for a proposed sale of 30,000 shares worth about $1.84 million, according to a new insider-related filing. The notice, which lets an affiliate signal they may sell restricted or control stock, did not show Kirsch had made any sales in the past three months.
Main risk is still there. In its latest quarterly filing, Liquidia said United Therapeutics is pressing for injunctive relief in multiple proceedings. That could mean pulling YUTREPIA from the market or cutting sales for one or both approved uses. If Liquidia loses, revenue could take a hit, and the stock, which is already priced for strong execution, could feel pressure.
Right now the bet is straightforward—and leaves little room for error. Investors are focused on whether prescriptions, patient starts, and payer access stay strong past the first-quarter spike. Even small signs of a slowdown in Wednesday’s update, or talk of legal risk, could outweigh fresh launch numbers.
